stockrow
Friday 6 November 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024.
- Revenue
- +13.0%
- EPS
- +21.1%
- Free cash flow
- +77.7%
- Total debt
- +7.63%
Quarter to September 2026, against a year earlier
6.86
0.06
+0.88%
Follow EOLS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.44 | 0.89 | 1.45 | 1.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
33.42 | (26.92) | (127.56) | (273.50) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.00 | 1.49 | 2.03 | 2.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.09) | (12.27) | (41.84) | (271.56) | |
EV/FCF |
(11.74) | (10.01) | (29.39) | (81.47) | |
Quick Ratio |
1.44 | 1.50 | 1.09 | 0.72 | |
Current Ratio |
1.90 | 2.04 | 1.70 | 1.42 | |
Net Debt/EBITDA |
12.90 | (28.07) | (77.00) | (22.92) | |
Debt/Assets |
64.68% | 70.89% | 63.20% | 55.28% | |
Debt/Equity |
(6.32) | (5.43) | (5.07) | (4.15) | |
Asset Turnover |
1.30 | 1.39 | 1.33 | 1.29 | |
Operating CF/Net income |
98.67 | 0.93 | 0.45 | 0.15 | |
Capex/Depreciation |
(0.74) | (0.55) | (0.16) | (0.53) | |
Interest Coverage |
1.06 | (1.72) | (1.09) | (1.98) | |
Research and Development Expense of Revenue |
3.85% | 3.06% | 2.25% | 2.52% | |
Selling, General and Administrative Expense of Revenue |
60.53% | 71.07% | 67.85% | 67.89% | |
Intangible Assets out of Total Assets |
0.31 | 0.31 | 0.27 | 0.24 | |
Share Based Compensation of Revenue |
5.70% | 7.00% | 6.69% | 7.19% | |
Graham Net Nets |
(0.25) | (0.41) | (0.24) | (0.23) | |
Graham Number |
2.56 | 2.58 | 2.34 | 2.46 | |
Earnings Yield |
(12.18%) | (16.30%) | (7.49%) | (5.87%) | |
Free Cash Flow Yield |
(11.83%) | (16.75%) | (4.79%) | (1.67%) | |
Revenue per Share |
1.40 | 1.12 | 1.28 | 1.18 | |
Operating CF per Share |
0.20 | (0.15) | (0.05) | (0.03) | |
Capex per Share |
(0.03) | (0.03) | (0.01) | (0.03) | |
Free Cash Flow per Share |
0.17 | (0.18) | (0.06) | (0.06) | |
Cash per Share |
0.83 | 0.76 | 0.69 | 0.63 | |
Shareholders Equity per Share |
(0.36) | (0.44) | (0.47) | (0.57) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.36) | (0.44) | (0.47) | (0.57) | |
Free Cash Flow |
10.66 | (11.64) | (4.09) | (3.75) | |
Working Capital |
67.61 | 70.90 | 68.81 | 59.36 | |
Capital Expenditures |
(2.17) | (1.69) | (0.50) | (1.81) | |
Net Current Asset Value |
(106.06) | (110.50) | (111.38) | (119.90) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
51.19 | 49.84 | 55.05 | 55.36 | |
Average Payables |
16.30 | 17.85 | 33.90 | 54.57 | |
Average Inventory |
19.56 | 17.41 | 33.68 | 57.84 | |
Average Assets |
229.22 | 217.00 | 238.41 | 251.41 | |
Average Common Equity |
(8.79) | (17.69) | (24.78) | (33.29) |
Columns are period end dates · fundamentals updated 6 Nov 2026